These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38364701)

  • 21. Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma.
    Jiang T; Shi J; Dong Z; Hou L; Zhao C; Li X; Mao B; Zhu W; Guo X; Zhang H; He J; Chen X; Su C; Ren S; Wu C; Zhou C
    J Hematol Oncol; 2019 Jul; 12(1):75. PubMed ID: 31299995
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Unique Genetic Mutation Characteristics Based on Large Panel Next-Generation Sequencing (NGS) Detection in Multiple Primary Lung Cancers (MPLC) Patients.
    Liang Z; Zeng G; Wan W; Deng B; Chen C; Li F; Lin G; Lin Y; Lin H; Mo G; Miao H
    Discov Med; 2023 Apr; 35(175):131-143. PubMed ID: 37188510
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation.
    Zhang B; Zeng J; Zhang H; Zhu S; Wang H; He J; Yang L; Zhou N; Zu L; Xu X; Song Z; Xu S
    Front Immunol; 2022; 13():974581. PubMed ID: 36159860
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Research Progress in Distinguishing Methods of Simultaneous Multiple Primary Lung Cancer and Intrapulmonary Metastasis].
    Wang J; Zhang T; Ding H; Dong G; Xu L; Jiang F
    Zhongguo Fei Ai Za Zhi; 2021 May; 24(5):365-371. PubMed ID: 34034461
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clonal expansion of shared T cell receptors reveals the existence of immune commonality among different lesions of synchronous multiple primary lung cancer.
    Wang Y; Huang Z; Li B; Xue J; Guo C; Bing Z; Zheng Z; Song Y; Xu Y; Huang G; Li H; Yu X; Xia Y; Li R; Si X; Zhang L; Li J; Song L; Xiong Y; Gu D; Song M; Zhou Z; Chen R; Feng Z; Bie Z; Li X; Yang H; Li S; Liang N
    Cancer Immunol Immunother; 2024 Apr; 73(6):111. PubMed ID: 38668781
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lineage tracing for multiple lung cancer by spatiotemporal heterogeneity using a multi-omics analysis method integrating genomic, transcriptomic, and immune-related features.
    Song Y; Zhou J; Zhao X; Zhang Y; Xu X; Zhang D; Pang J; Bao H; Ji Y; Zhan M; Wang Y; Ou Q; Hu J
    Front Oncol; 2023; 13():1237308. PubMed ID: 37799479
    [TBL] [Abstract][Full Text] [Related]  

  • 27. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
    Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
    Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Next-generation sequencing facilitates differentiating between multiple primary lung cancer and intrapulmonary metastasis: a case series.
    Liu C; Liu C; Zou X; Shao L; Sun Y; Guo Y
    Diagn Pathol; 2021 Mar; 16(1):21. PubMed ID: 33706781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer.
    Yoshimura K; Inoue Y; Tsuchiya K; Karayama M; Yamada H; Iwashita Y; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
    Lung Cancer; 2020 Mar; 141():21-31. PubMed ID: 31931443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lack of evolutionary convergence in multiple primary lung cancer suggests insufficient specificity of personalized therapy.
    Cheng H; Guo Z; Zhang X; Wang XJ; Li Z; Huo WW; Zhong HC; Li XJ; Wu XW; Li WH; Chen ZW; Wu TC; Gan XF; Zhong BL; Lyubetsky VA; Rusin LY; Yang J; Zhao Q; Cao QD; Yang JR
    J Genet Genomics; 2023 May; 50(5):330-340. PubMed ID: 36414223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. B7-1 and programmed cell death-ligand 1 in primary and lymph node metastasis lesions of non-small cell lung carcinoma.
    Yamada T; Miki Y; Suzuki M; Kondoh O; Saito-Koyama R; Ono K; Okada Y; Sasano H
    Cancer Med; 2022 Jan; 11(2):479-491. PubMed ID: 34907653
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular Identification and Genetic Characterization of Early-Stage Multiple Primary Lung Cancer by Large-Panel Next-Generation Sequencing Analysis.
    Pei G; Li M; Min X; Liu Q; Li D; Yang Y; Wang S; Wang X; Wang H; Cheng H; Cao S; Huang Y
    Front Oncol; 2021; 11():653988. PubMed ID: 34109114
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multidimensional profiling depicts infiltrating immune cell heterogeneity in the tumor microenvironment of stage IA non-small cell lung cancer.
    Duan J; Lv G; Zhu N; Chen X; Shao Y; Liu Y; Zhao W; Shi Y
    Thorac Cancer; 2022 Apr; 13(7):947-955. PubMed ID: 35150094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
    Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
    Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Landscape of Genomic Alterations and PD-L1 Expression in Early-Stage Non-Small-Cell Lung Cancer (NSCLC)-A Single Center, Retrospective Observational Study.
    Stephan-Falkenau S; Streubel A; Mairinger T; Kollmeier J; Misch D; Thiel S; Bauer T; Pfannschmidt J; Hollmann M; Wessolly M; Blum TG
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293366
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.
    Haratani K; Hayashi H; Tanaka T; Kaneda H; Togashi Y; Sakai K; Hayashi K; Tomida S; Chiba Y; Yonesaka K; Nonagase Y; Takahama T; Tanizaki J; Tanaka K; Yoshida T; Tanimura K; Takeda M; Yoshioka H; Ishida T; Mitsudomi T; Nishio K; Nakagawa K
    Ann Oncol; 2017 Jul; 28(7):1532-1539. PubMed ID: 28407039
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnosis of multiple primary lung cancer: a systematic review.
    Xue X; Liu Y; Pan L; Wang Y; Wang K; Zhang M; Wang P; Wang J
    J Int Med Res; 2013 Dec; 41(6):1779-87. PubMed ID: 24265329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 39. [Correlation between Immune Microenvironment Features and EGFR Mutation Status 
in Lung Adenocarcinoma].
    Zhu H; Chen P; Dong G; Meng F; Xia Z; You J; Kong X; Wu J; Yuan F; Yu X; Sun Q; Ji J; Wang S; Liu T; Xu L
    Zhongguo Fei Ai Za Zhi; 2023 Mar; 26(3):204-216. PubMed ID: 37035883
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lymphovascular Invasion Is Associated With Mutational Burden and PD-L1 in Resected Lung Cancer.
    Mitchell KG; Negrao MV; Parra ER; Li J; Zhang J; Dejima H; Vaporciyan AA; Swisher SG; Weissferdt A; Antonoff MB; Cascone T; Roarty E; Wistuba II; Heymach JV; Gibbons DL; Zhang J; Sepesi B
    Ann Thorac Surg; 2020 Feb; 109(2):358-366. PubMed ID: 31550464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.